CDKN2A and cancer: Recent surveys of cancer genome landscapes have shown that alterations of a particular pathway can involve many different genes and many different kinds of disruptions—for example, RB1 mutation, RB1 methylation, or CDKN2A deletion can all lead to aberrant cell proliferation [36].